15 completed, 5 unknown, 4 recruiting, 3 withdrawn. 30 Phase 2, 4 Phase 1, 4 Phase 3.
Follow Olfaction Disorders: new trials by email Literature Review of Olfaction Disorders trials Research Report on Olfaction Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT): Open Label Trigeminal Nerve Stimulation-enhanced Smell Training - Olfactory Impairment | Phase 2 | Recruiting | Medical University of South Carolina | 60 | 2026-07-10 | 2026-08-12 |
| Impact of Smell Testing on Health Outcomes Patient-centered information and education - Olfactory Dysfunction, Wellbeing | Phase 2 | Recruiting | Monell Chemical Senses Center | 1000 | 2026-05-29 | 2026-10-06 |
| Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction Sodium Citrate, Normal Saline, Olfactory Training Kit - "The Olfactory Kit, by AdvancedRx" - Long Haul COVID-19, Post-Acute COVID-19 Syndrome | Phase 2 | Active not recruiting | University of North Carolina, Chapel Hill | 60 | 2023-12-01 | 2025-02-20 |
| Stellate Ganglion Block for COVID-induced Parosmia Stellate Ganglion Block, Placebo Sham Injection - COVID-19-Induced Parosmia | Phase 2 | Completed | Washington University School of Medicine | 48 | 2023-10-25 | 2025-11-10 |
| Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID) Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO) - Smell Dysfunction, Olfactory Disorder | Phase 2 / Phase 3 | Recruiting | Medical University of South Carolina | 145 | 2023-10-02 | 2026-04-02 |
| Study of CYR-064 Versus Placebo in Patients. CYR-064 - Hyposmia | Phase 2 | Completed | Cyrano Therapeutics, Inc. | 151 | 2023-09-26 | 2026-08-31 |
| Directed Topical Drug Delivery for Treatment for PASC Hyposmia Beclomethasone, Placebo, Microsponge - Post Acute Sequelae Covid-19 Hyposmia | Phase 2 | Completed | Duke University | 16 | 2023-09-05 | 2026-03-19 |
| Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3) theophylline, Placebo - COVID-19 | Phase 2 | Completed | Washington University School of Medicine | 77 | 2022-11-22 | 2025-08-20 |
| Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction Stellate Ganglion Block - Anosmia, Hyposmia | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 20 | 2022-09-01 | 2026-02-12 |
| Ivermectin Nasal Drops in Post COVID-19 Parosmia Ivermectin Topical, Budesonide Nasal - Parosmia | Phase 2 | Unknown | Menoufia University | 60 | 2022-07-01 | 2022-05-11 |
| Vitamin D Nasal Drops in Post COVID-19 Parosmia Vitamin D3, Budesonide nasal spray - Parosmia | Phase 2 | Unknown | Menoufia University | 60 | 2022-06-01 | 2022-05-11 |
| Preparation and Characterization Intranasal Film Loaded With Steroid as a Local Treatment of Anosmia in Compare to Insulin Intranasal Film Prednisolone - Smell Loss | Phase 1 / Phase 2 | Completed | Deraya University | 200 | 2022-03-01 | 2023-06-01 |
| Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction Gabapentin gelatin capsules 300mg, Placebo - COVID-19, Olfactory Disorder | Phase 2 | Completed | Washington University School of Medicine | 68 | 2022-01-10 | 2025-03-04 |
| Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia Fluvoxamine, Placebo - COVID-19, Olfactory Disorder | Phase 2 | Withdrawn | Washington University School of Medicine | 2021-12-14 | 2022-03-11 | |
| Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19 Smell Retraining, Budesonide - Dysosmia, Anosmia | Phase 1 / Phase 2 | Terminated | Amanda Stapleton | 20 | 2021-09-30 | 2024-06-13 |
| Factors Influencing the Prognosis of Olfactory Dysfunction After Upper Sensation methylprednisolone, budesonide atomization suspension - Outcome | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 90 | 2021-06-02 | 2021-06-09 |
| Coronavirus Smell Therapy for Anosmia Recovery Budesonide, High-Concentration Essential Oil, Placebo - Anosmia | Phase 2 | Withdrawn | Washington University School of Medicine | 2021-06-01 | 2021-03-02 | |
| Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia intranasal spray ivermectin - Anosmia | Phase 2 / Phase 3 | Unknown | South Valley University | 117 | 2021-04-20 | 2022-04-22 |
| Smell in Covid-19 and Efficacy of Nasal Theophylline Theophylline Powder, Placebo Comparator - Covid19, Anosmia | Phase 2 | Completed | Washington University School of Medicine | 51 | 2021-03-15 | 2023-05-24 |
| Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis | Phase 1 / Phase 2 | Unknown | All Natural Medicine Clinic, LLC | 2000 | 2021-03-01 | 2021-05-26 |
Showing 20 of 30. Sign in to see all of them.
Anosmia (23) · COVID-19 (14) · Post-Acute COVID-19 Syndrome (3) · Ageusia (2) · Infections (2) · Virus Diseases (2) · Abdominal Pain (1) · Alzheimer Disease (1) · Anorexia (1) · Anxiety Disorders (1) · Arthralgia (1) · Arthritis, Reactive (1) · Bipolar Disorder (1) · COVID-19 stress syndrome (1)
Pathological Conditions, Signs and Symptoms (30) · Signs and Symptoms (30) · Nervous System Diseases (29) · Neurologic Manifestations (29) · Sensation Disorders (29) · Infections (15) · Respiratory Tract Diseases (14) · Respiratory Tract Infections (14) · Coronaviridae Infections (13) · Coronavirus Infections (13) · Lung Diseases (13) · Nidovirales Infections (13) · Pneumonia (13) · Pneumonia, Viral (13)
Olfactory Training (4) · Budesonide (3) · Saline Solution (3) · Theophylline (3) · Mepivacaine (2) · Beclomethasone (1) · Cholecalciferol (1) · Dronabinol (1) · Educational Status (1) · Fluvoxamine (1) · Gonadotropin-Releasing Hormone (1) · Hesperidin (1) · Ivermectin (1) · Methylprednisolone (1) · Prednisolone (1)
Washington University School of Medicine (8) · Medical University of South Carolina (2) · Menoufia University (2) · University of North Carolina, Chapel Hill (2) · Alberta Health services (1) · All Natural Medicine Clinic, LLC (1) · Amanda Stapleton (1) · Centre Hospitalier Universitaire Saint Pierre (1) · Cyrano Therapeutics, Inc. (1) · Deraya University (1) · Duke University (1) · Icahn School of Medicine at Mount Sinai (1) · Ivan FN Hung MD (1) · Massachusetts General Hospital (1) · Monell Chemical Senses Center (1)
United States (19) · Egypt (5) · Canada (2) · Belgium (1) · China (1) · Hong Kong (1) · Switzerland (1)
Jay F Piccirillo, MD (3) · Adam M Zanation, MD (1) · Alfred-Marc Iloreta, MD (1) · Amanda L Stapleton, MD (1) · Bradley Goldstein, MD, PhD (1) · Brent A. Senior, MD, FACS, FARS (1) · Danielle Reed (1) · Ingrid H. de Kock, MD (1) · Jay F Piccirillo, M.D., FACS (1) · Jocelyn Dupuis, MD (1) · Mas Takashima, MD (1) · Mihaela Horoi, PhD (1) · Nelly Pitteloud, MD (1) · Nyssa Farrell, MD (1) · Pamela Dalton (1)
PMID 18377764, PMID 19359985, PMID 21191261, PMID 21343383, PMID 22377744, PMID 23165381, PMID 23731850, PMID 27923495, PMID 33225989, PMID 35797024, PMID 35904632, PMID 36048943, PMID 36062970, PMID 36063364, PMID 36164334, PMID 37733356, PMID 40504522
R01DC021179 (1), R44DC022498 (1)